Zenas BioPharma, Inc. (ZBIO) AI Stock Analysis

• Market Cap: $398.26M
• Dividend Yield: N/A
• Average Volume (3M): 137.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 130
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -3.90
• Shares Outstanding: 41,834,183
• 10 Day Avg. Volume: 141,234
• 30 Day Avg. Volume: 137,510
• PEG Ratio: 0.11
• Price to Book (P/B): 1.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $36.67
• Price Target Upside: 285.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 49 Neutral
• Price Target: $9.50 ▼(-0.21%Downside)

Zenas BioPharma's overall score reflects its financial challenges, including declining revenue and high cash burn. However, positive corporate events and a neutral technical outlook provide some balance. The company's potential in biotechnology, highlighted by upcoming clinical trials, offers a future growth opportunity despite current difficulties.

Positive Factors

Clinical Validation

Encouraging Phase 2 trial results for wAIHA strengthen the proof-of-concept for obexelimab, showcasing its potential effectiveness without major safety concerns.

Market Expansion

The potential to expand the biologics market uptake through obexelimab's first-in-class approach provides long-term growth opportunities for ZBIO.

Therapeutic Innovation

Obexelimab's design to inhibit cellular activity in autoimmune diseases without B cell depletion could offer a safer treatment option.

Negative Factors

Competitive Pressure

ZBIO shares have faced pressure due to investor concerns on competition for obexelimab in IgG4-RD.

Data Timeline Concerns

The lack of near-term data catalysts has contributed to cautious investor sentiment regarding ZBIO.

Zenas BioPharma, Inc. Business Overview & Revenue Model

Company Description

Zenas BioPharma, Inc. (ZBIO) is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of autoimmune and rare diseases. The company leverages scientific advancements to create a pipeline of biologic products that address significant unmet medical needs. Zenas BioPharma operates within the sectors of biotechnology and pharmaceuticals, aiming to improve patient outcomes through novel therapeutics.

How the Company Makes Money

Zenas BioPharma, Inc. generates revenue through the development and commercialization of its biologic therapies. The company earns money primarily through the sale of its pharmaceutical products once they receive regulatory approval and are brought to market. Additional revenue streams may include partnerships and collaborations with other pharmaceutical companies, which can provide funding through upfront payments, milestone payments, and royalties on sales. Strategic partnerships can also enhance product development efficiency and expand market reach, contributing to the company's financial growth.

Zenas BioPharma, Inc. Financial Statement Overview

Summary

Zenas BioPharma is experiencing substantial revenue decline and persistent losses, with a strong equity recovery providing some balance sheet stability. Cash flow challenges, driven by significant cash burn, underscore the need for operational improvements. The company must address its revenue and cash flow issues to ensure long-term sustainability.

Income Statement

Zenas BioPharma has shown a significant decline in revenue from $50 million in 2023 to $5 million in 2024, indicating a severe contraction. The gross profit margin remains high due to zero cost of goods sold, yet the company faces substantial operating losses with negative EBIT and net income, highlighting ongoing profitability challenges.

Balance Sheet

The company has a strong equity position with a debt-to-equity ratio of only 0.003, suggesting low financial leverage. However, the negative equity in previous years indicates past difficulties, although recent improvements in stockholder's equity to $312 million show significant recovery. The equity ratio of approximately 84% is a positive indicator of financial stability.

Cash Flow

Zenas BioPharma's free cash flow remains negative, with a decline in operating cash flow from -$30 million to -$120 million. While financing activities have injected significant cash, the operational cash burn is a concern. The operating cash flow to net income ratio is negative, reflecting inefficiency in converting income into cash.

Breakdown
Dec 2024	Dec 2023	Dec 2022
Income Statement		Total Revenue
5.00M	50.00M	0.00
	Gross Profit
5.00M	50.00M	0.00
	EBIT
-163.89M	-37.15M	-76.20M
	EBITDA
-163.89M	-27.03M	-75.12M
	Net Income Common Stockholders
-156.13M	-37.12M	-119.28M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
350.77M	56.86M	67.21M
	Total Assets
369.97M	68.18M	74.58M
	Total Debt
1.00M	21.11M	1.53M
	Net Debt
-318.74M	-35.74M	-65.68M
	Total Liabilities
57.51M	293.90M	266.87M
	Stockholders Equity
312.46M	-225.72M	-192.29M
Cash Flow		Free Cash Flow
-119.81M	-30.55M	-67.85M
	Operating Cash Flow
-119.67M	-30.53M	-65.65M
	Investing Cash Flow
-30.55M	-17.00K	-2.20M
	Financing Cash Flow
412.96M	20.12M	59.39M

Zenas BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETON	64 Neutral	$463.41M	―	-22.95%	―	40.88%	-579.73%
AMLX	59 Neutral	$456.40M	―	-83.24%	―	-100.32%	-197.69%
Sector *	53 Neutral	$5.25B	3.24	-45.38%	2.81%	16.79%	-0.06%
ZBIO	49 Neutral	$398.26M	―	-115.47%	―	―	―
CKPT	45 Neutral	$370.71M	―	-1869.55%	―	-60.19%	56.60%
TRML	45 Neutral	$473.70M	―	-26.14%	―	―	74.59%
RAPP	44 Neutral	$446.73M	―	-33.14%	―	―	―

Zenas BioPharma, Inc. Corporate Events

Zenas BioPharma to Present at Jefferies Conference

Zenas BioPharma announced its participation in the Jefferies Global Healthcare Conference in June 2025, where it will present its investor presentation. The company is advancing its clinical trials for Obexelimab, a potentially highly differentiated therapy for autoimmune diseases, with significant upcoming data readouts expected in late 2025 and mid-2026. These developments could position Zenas BioPharma as a competitive player in the biotechnology market, potentially impacting stakeholders positively.

The most recent analyst rating on (ZBIO) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.